Daily Sepsis Research Analysis
Three high-impact studies address core sepsis management questions: a meta-analysis suggests vasopressors started 1–3 hours after septic shock diagnosis may reduce short-term mortality; a PROSPERO-registered meta-analysis finds prolonged meropenem infusion lowers mortality and improves clinical outcomes versus intermittent dosing; and a large cohort validates SCAI shock staging for risk stratification in sepsis, performing similarly to SOFA.
Summary
Three high-impact studies address core sepsis management questions: a meta-analysis suggests vasopressors started 1–3 hours after septic shock diagnosis may reduce short-term mortality; a PROSPERO-registered meta-analysis finds prolonged meropenem infusion lowers mortality and improves clinical outcomes versus intermittent dosing; and a large cohort validates SCAI shock staging for risk stratification in sepsis, performing similarly to SOFA.
Research Themes
- Optimal timing of vasopressor initiation in septic shock
- Beta-lactam infusion strategy (prolonged vs intermittent) and outcomes
- Universal shock severity staging (SCAI) applied to sepsis
Selected Articles
1. Extremely early initiation of vasopressors might not decrease short-term mortality for adults with septic shock: a systematic review and meta-analysis.
Across 11 studies (6,661 patients), there was no overall mortality benefit to very early vasopressor initiation; however, initiation within 1–3 hours after septic shock diagnosis was associated with reduced short-term mortality in subgroup analyses. Considerable heterogeneity underscores the need for standardized definitions and protocols.
Impact: This synthesis refines timing recommendations for vasopressors in septic shock, a universally encountered ICU decision, and highlights a specific actionable window (1–3 hours) for potential benefit.
Clinical Implications: Consider initiating vasopressors within 1–3 hours of septic shock diagnosis when feasible, while ensuring adequate volume assessment; avoid assuming benefit from “extremely early” initiation without context. Institutions should standardize time-zero definitions and protocols.
Key Findings
- No overall short-term mortality difference between very early and later vasopressor initiation in pooled analysis (OR 0.66; 95% CI 0.36–1.19; I² 82%).
- Subgroup with initiation 1–3 hours after diagnosis showed lower mortality (OR 0.70; 95% CI 0.60–0.82; I² 0%).
- Using septic shock diagnosis as time zero also favored earlier initiation (OR 0.64; 95% CI 0.48–0.85; I² 39%).
Methodological Strengths
- Comprehensive search across multiple databases with meta-analysis.
- Predefined subgroup analyses addressing timing definitions.
Limitations
- High heterogeneity across studies and variable definitions of 'early' initiation.
- Mixture of RCTs and quasi-experimental/observational designs may introduce confounding.
Future Directions: Conduct standardized, protocolized RCTs defining time zero uniformly and comparing initiation windows (e.g., ≤1 h vs 1–3 h vs >3 h) with patient-centered outcomes.
BACKGROUND: The optimal timing for initiating vasopressor therapy in patients with septic shock remains unclear. This study aimed to assess the impact of early versus late vasopressor initiation on clinical outcomes. METHODS: A systematic review and meta-analysis were conducted by searching PubMed, Embase, and Cochrane databases. Studies comparing early and late vasopressor administration in septic shock patients were included. The primary outcome was short-term mortality, and subgroup analyses were performed based on different initiation timings. RESULTS: Eleven studies with 6,661 patients were included. Different studies define the 'early administration' timeframe variously, ranging from one to seven hours. No significant difference in short-term mortality was observed between early and late administration in the combined analysis of 3,757 patients from two RCTs and three quasi-experimental studies (OR: 0.66, 95% CI: [0.36, 1.19], I²: 82%). However, lower mortality was found in subgroups with early but not extremely early initiation (one to three hours, OR: 0.70, 95% CI: [0.60, 0.82], I²: 0%), and those using septic shock diagnosis as time zero (OR: 0.64, 95% CI: [0.48, 0.85], I²: 39%). CONCLUSION: Our findings found that earlier initiation of vasopressor therapy, particularly within one to three hours after the diagnosis of septic shock, may be associated with reduced short-term mortality in certain subgroups. However, due to the heterogeneity in study definitions and potential confounding factors, these results should be interpreted cautiously. Further standardized investigations are warranted to precisely determine the optimal timing for vasopressor initiation to maximize survival outcomes in patients with septic shock.
2. Impact of prolonged versus intermittent infusion of meropenem on mortality and clinical outcomes in patients with severe infection: A systematic review and meta-analysis.
Across 14 studies (n=1,698), prolonged meropenem infusion reduced all-cause mortality and improved clinical response and microbiologic eradication versus intermittent dosing, with no difference in ICU or hospital length of stay. Benefits were most evident in lower-severity patients (APACHE II <20).
Impact: Provides quantitative clinical support for PK/PD-based carbapenem dosing strategies, addressing a long-standing critical care question with evidence of mortality benefit.
Clinical Implications: Consider prolonged infusion protocols for meropenem, particularly in lower-severity patients, integrated with antimicrobial stewardship and potential therapeutic drug monitoring to optimize time above MIC.
Key Findings
- Prolonged infusion reduced mortality versus intermittent dosing (RR 0.81; 95% CI 0.68–0.98).
- Clinical improvement (RR 1.35; 95% CI 1.11–1.64) and microbiologic eradication (RR 1.19; 95% CI 1.08–1.32) favored prolonged infusion.
- No significant differences in ICU or hospital length of stay; benefits more pronounced in APACHE II <20.
Methodological Strengths
- Prospective registration (PROSPERO: CRD42023445360) and random-effects meta-analysis.
- Risk of bias appraisal tailored to study design (modified JADAD, Newcastle–Ottawa Scale).
Limitations
- Mix of RCTs and observational studies may introduce residual confounding.
- Heterogeneous dosing regimens and patient populations; limited LOS effects despite mortality benefit.
Future Directions: Large, CONSORT-compliant RCTs with standardized prolonged-infusion protocols and TDM to verify mortality effects across severity strata and pathogens.
OBJECTIVES: To compare the clinical outcomes of patients with severe infection treated with prolonged or intermittent infusion of meropenem. METHODS: PubMed, Embase, and Cochrane Central databases were searched until July 2023. Randomized controlled trials (RCTs) or observational studies comparing prolonged versus intermittent infusion of meropenem were considered eligible. The primary outcomes included all-cause mortality and clinical improvement, while secondary outcomes encompassed hospital and intensive care unit (ICU) stay duration, microbial eradication rate, and adverse events. A meta-analysis was conducted using a random-effects model. The risk of bias of included studies was assessed using the modified JADAD scale for RCTs and the Newcastle-Ottawa Scale for observational studies. RESULTS: Fourteen studies were included, with a total of 1698 patients. Prolonged infusion of meropenem was associated with a significantly lower mortality rate compared to intermittent infusion (RR = 0.81, 95 % CI: 0.68-0.98). It also significantly improved clinical improvement rates (RR = 1.35, 95 % CI: 1.11-1.64) and microbial eradication rates (RR = 1.19, 95 % CI: 1.08-1.32). There were no statistically significant differences in ICU length of stay or hospital length of stay. Subgroup analyses showed that prolonged infusion was significantly associated with lower mortality and better clinical improvement rates in patients with an APACHE II score <20. CONCLUSIONS: Prolonged infusion of meropenem is more effective than intermittent infusion in reducing mortality, improving clinical outcomes, and enhancing microbial eradication, without increasing adverse events. These benefits are particularly evident in patients with lower disease severity (APACHE II < 20), emphasizing the importance of patient stratification in optimizing treatment strategies. REGISTRATION: This systematic review and meta-analysis is registered with PROSPERO (number: CRD42023445360).
3. Validation of SCAI Shock Staging in Critically Ill Medical Intensive Care Unit Patients With Sepsis and Septic Shock.
In 3,079 ICU patients with sepsis or septic shock, SCAI shock staging showed stepwise worsening outcomes, with stages D and E independently predicting higher 30-day mortality (adjusted HRs 1.6 and 3). SCAI performed similarly to SOFA for ICU mortality prediction, supporting its use as a universal shock grading system.
Impact: Demonstrates that SCAI shock staging, originally designed for cardiogenic shock, generalizes to sepsis with prognostic validity comparable to SOFA, enabling cross-etiology risk stratification.
Clinical Implications: SCAI shock staging can be adopted alongside SOFA to stratify sepsis/septic shock severity and guide triage, monitoring intensity, and escalation decisions, especially for stages D/E.
Key Findings
- Among 3,079 patients, SCAI stages A–E distribution: 9%, 12%, 25%, 49%, 5%; overall 30-day mortality 24%.
- Adjusted hazard ratios for 30-day mortality were significant for stages D (HR 1.6) and E (HR 3).
- SCAI shock staging had similar discriminative performance to SOFA for ICU mortality (no significant AUC difference).
Methodological Strengths
- Large cohort with Sepsis-III criteria and formal comparison to SOFA.
- Stage-wise analysis with adjusted hazard ratios demonstrating prognostic gradation.
Limitations
- Single-center historical cohort limits generalizability.
- Potential residual confounding and missingness inherent to retrospective EHR data.
Future Directions: Prospective multicenter validation and integration of SCAI staging into sepsis care pathways; evaluate additive value over SOFA for decision support.
PURPOSE: This study evaluated the predictive value of SCAI shock staging for mortality in patients with sepsis and septic shock admitted to the medical ICU. MATERIALS AND METHODS: This is a single-center historical cohort study. We analyzed data for adults (≥18-year-old) admitted to the medical ICU at Mayo Clinic St. Mary's campus with sepsis between June 1, 2018, and December 31, 2021. Sepsis was identified using the Sepsis-III criteria. Patients were stratified based on SCAI shock staging. Our primary outcome was all-cause 30-day mortality. RESULTS: We identified 3079 eligible adult patients with sepsis or septic shock. The distribution of SCAI shock stages A through E was 9%, 12%, 25%, 49%, and 5%, respectively. The overall 30-day mortality was 24%. There was progression in all outcomes including ICU, hospital and 30-day mortality across SCAI shock stages. However, only SCAI shock stages D and E, had statistically significant adjusted HRs of 1.6 and 3, respectively. When compared to SOFA score, SCAI shock staging performed similarly in predicting ICU mortality with no statistically significant difference in AUCs, CONCLUSIONS: Our results support the use of SCAI shock staging in critically ill medical patients with sepsis and septic shock for risk stratification. We propose that the SCAI shock staging may be used as a universal system for grading the severity of shock in critically ill patients regardless of etiology.